Durata Therapeutics, Inc.
http://www.duratatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Durata Therapeutics, Inc.
Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market
Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.
BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More
Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.
BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More
Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.
Roche Looks To Defy The Odds In Parkinson’s Study
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice